PLATO trial demonstrated that ticagrelor was more effective in reducing CV outcomes in patients with acute coronary syndrome (ACS).
Ticagrelor carries a lower risk of bleeding. More preferred option in older patients and those with diabetes
We are dedicated to driving innovation in healthcare through cutting-edge research and biotechnological solutions. Our mission is to improve lives with science-backed therapies and a commitment to excellence.
F/10 Moonlight Complex,
Gurukul Road,
Ahmedabad - 380013
Gujarat, India
Sachin Patel
Sanjay Kumar Jaiswal
therapeiabiosciences@gmail.com
+91 99780 47841
